JP Morgan Chase’s Pacira BioSciences PCRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$11.3M Buy
442,012
+95,315
+27% +$2.41M ﹤0.01% 2754
2026
Q2
$8.7M Buy
346,697
+106,328
+44% +$2.51M ﹤0.01% 2942
2026
Q1
$5.59M Sell
240,369
-48,282
-17% -$1.07M ﹤0.01% 3234
2025
Q4
$7.47M Sell
288,651
-147,547
-34% -$3.51M ﹤0.01% 2973
2025
Q3
$11.2M Buy
436,198
+94,192
+28% +$2.31M ﹤0.01% 2622
2025
Q2
$8.17M Sell
342,006
-310,470
-48% -$7.83M ﹤0.01% 2741
2025
Q1
$16.2M Sell
652,476
-103,700
-14% -$2.48M ﹤0.01% 2093
2024
Q4
$14.2M Buy
756,176
+20,202
+3% +$355K ﹤0.01% 2377
2024
Q3
$11.1M Buy
735,974
+135,363
+23% +$2.31M ﹤0.01% 2520
2024
Q2
$17.2M Buy
600,611
+515,539
+606% +$14.7M ﹤0.01% 1993
2024
Q1
$2.49M Sell
85,072
-55,578
-40% -$1.71M ﹤0.01% 3693
2023
Q4
$4.75M Hold
140,650
– – ﹤0.01% 3155
2023
Q3
$2.79M Sell
90,838
-38,592
-30% -$1.39M ﹤0.01% 3304
2023
Q2
$5.19M Buy
129,430
+45,533
+54% +$1.88M ﹤0.01% 2842
2023
Q1
$3.42M Buy
83,897
+4,253
+5% +$169K ﹤0.01% 3129
2022
Q4
$3.07M Buy
79,644
+204
+0.3% +$9.9K ﹤0.01% 3238
2022
Q3
$4.23M Buy
79,440
+9,034
+13% +$502K ﹤0.01% 2898
2022
Q2
$4.1M Buy
70,406
+9,518
+16% +$623K ﹤0.01% 2974
2022
Q1
$4.65M Buy
60,888
+9,350
+18% +$623K ﹤0.01% 3083
2021
Q4
$3.1M Buy
51,538
+570
+1% +$31.4K ﹤0.01% 3480
2021
Q3
$2.86M Sell
50,968
-1,963
-4% -$113K ﹤0.01% 3495
2021
Q2
$3.21M Sell
52,931
-587
-1% -$37.2K ﹤0.01% 3429
2021
Q1
$3.75M Buy
53,518
+8,803
+20% +$629K ﹤0.01% 3227
2020
Q4
$2.68M Sell
44,715
-6,857
-13% -$402K ﹤0.01% 3288
2020
Q3
$3.06M Buy
51,572
+30,649
+146% +$1.78M ﹤0.01% 2953
2020
Q2
$1.1M Sell
20,923
-3,720
-15% -$155K ﹤0.01% 3473
2020
Q1
$826K Sell
24,643
-913
-4% -$37.9K ﹤0.01% 3547
2019
Q4
$1.16M Buy
25,556
+2,606
+11% +$111K ﹤0.01% 3774
2019
Q3
$874K Sell
22,950
-135,063
-85% -$5.39M ﹤0.01% 3937
2019
Q2
$6.94M Buy
158,013
+144,108
+1,036% +$6.12M ﹤0.01% 2400
2019
Q1
$529K Sell
13,905
-409
-3% -$16K ﹤0.01% 4203
2018
Q4
$615K Buy
14,314
+4,432
+45% +$207K ﹤0.01% 4050
2018
Q3
$485K Buy
9,882
+1,218
+14% +$52.6K ﹤0.01% 4320
2018
Q2
$278K Buy
8,664
+121
+1% +$4.18K ﹤0.01% 4459
2018
Q1
$266K Sell
8,543
-127,519
-94% -$4.54M ﹤0.01% 4291
2017
Q4
$6.21M Sell
136,062
-61,640
-31% -$2.44M ﹤0.01% 2521
2017
Q3
$7.65M Buy
197,702
+21,277
+12% +$856K ﹤0.01% 2229
2017
Q2
$8.42M Buy
176,425
+23,700
+16% +$1.1M ﹤0.01% 2100
2017
Q1
$6.96M Sell
152,725
-50,838
-25% -$2.2M ﹤0.01% 2205
2016
Q4
$6.58M Buy
203,563
+26,838
+15% +$896K ﹤0.01% 2252
2016
Q3
$6.05M Buy
176,725
+82,701
+88% +$3.24M ﹤0.01% 2130
2016
Q2
$3.17M Sell
94,024
-43,467
-32% -$2.14M ﹤0.01% 2584
2016
Q1
$7.28M Sell
137,491
-2,052
-1% -$120K ﹤0.01% 1986
2015
Q4
$10.7M Sell
139,543
-17,854
-11% -$1.01M ﹤0.01% 1789
2015
Q3
$6.47M Sell
157,397
-55,650
-26% -$3.41M ﹤0.01% 2084
2015
Q2
$15.1M Buy
213,047
+124,772
+141% +$9.8M ﹤0.01% 1621
2015
Q1
$7.84M Sell
88,275
-34,762
-28% -$3.53M ﹤0.01% 2073
2014
Q4
$10.9M Sell
123,037
-150,210
-55% -$14.2M ﹤0.01% 1900
2014
Q3
$26.5M Sell
273,247
-74,283
-21% -$7.23M 0.01% 1273
2014
Q2
$31.9M Buy
347,530
+20,771
+6% +$1.58M 0.01% 1077
2014
Q1
$22.9M Buy
326,759
+60,554
+23% +$4.12M 0.01% 1240
2013
Q4
$15.3M Sell
266,205
-30,590
-10% -$1.61M ﹤0.01% 1501
2013
Q3
$14.3M Buy
296,795
+29,996
+11% +$1.09M ﹤0.01% 1525
2013
Q2
$7.74M Hold
266,799
– – ﹤0.01% 1841

Other funds holding PCRX

JP Morgan Chase's PCRX Position: Q3 2026 in Review

JP Morgan Chase increased its Pacira BioSciences (PCRX) stake by 27% in Q3 2026, buying an estimated $2.41M and bringing the position to 442,012 shares worth $11.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2754.

JP Morgan Chase first reported a position in PCRX in Q2 2013 and has held it in 54 quarters since. The position peaked at $31.9M in Q2 2014. 258 funds tracked by Wall St. Rank hold PCRX as of Q3 2026.

  • JP Morgan Chase held 442,012 shares of Pacira BioSciences worth $11.3M as of Q3 2026.
  • JP Morgan Chase bought 95,315 Pacira BioSciences shares in Q3 2026, an estimated $2.41M.
  • Pacira BioSciences made up ﹤0.01% of JP Morgan Chase's portfolio in Q3 2026, its #2754 holding.
  • JP Morgan Chase first reported a position in Pacira BioSciences in Q2 2013 and has held it in 54 quarters since.
  • JP Morgan Chase's Pacira BioSciences position peaked at $31.9M in Q2 2014.
  • 258 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2026.

Based on JP Morgan Chase's 13F filing for Q3 2026, filed 12 Nov 2026.